Elevance Health (XTER:A58) ROCE %: % (As of Mar. 2026)


XTER:A58 Elevance Health Inc XTER:A58
89 GF Score
Price €343.40
GF Value €441.91
Valuation Modestly Undervalued
! 7 Warning Signs
View Full Analysis

What is Elevance Health ROCE %?

Elevance Health XTER:A58 +1.21% 89 ROCE % is % as of Mar. 2026. GuruFocus rates XTER:A58 with a GF Score™ of 89/100 and a GF Value™ of €441.91 (Modestly Undervalued). The stock has 7 warning signs investors should review.

ROCE % does not apply to banks and insurance companies.

XTER:A58
89GF Score
Elevance Health Inc XTER:A58
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of % mean?
Elevance Health (XTER:A58) has a ROCE % of % as of Mar. 2026.
Is Elevance Health's ROCE % too high?
Elevance Health's current ROCE % is %. Overall, Elevance Health has a GF Score™ of 89/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Elevance Health's ROCE % compare to CI and CVS?
Elevance Health's ROCE % of % can be compared against companies in the Healthcare Plans industry. The industry median ROCE % is 9.38. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Healthcare Plans company?
The median ROCE % among Healthcare Plans companies is 9.38, based on 15 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Healthcare Plans industry, the median ROCE % is 9.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Elevance Health's current ROCE % is %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Elevance Health stock overvalued right now?
Based on GuruFocus' analysis, Elevance Health (XTER:A58) is currently considered Modestly Undervalued. The stock's GF Value™ is €441.91, compared to a current price of €343.40 — trading 22.3% below its estimated fair value. The current ROCE % is %. Elevance Health's overall GF Score™ is 89/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Elevance Health (XTER:A58), the current ROCE % is % as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Elevance Health (XTER:A58) Overvalued in 2026?

Based on GuruFocus' analysis, Elevance Health stock appears to be undervalued. The current stock price of €343.40 is trading 22.3% below its estimated GF Value™ of €441.91. GuruFocus considers Elevance Health to be Modestly Undervalued.

Key valuation signals for XTER:A58:

  • ROCE %: %
  • GF Value™: €441.91 vs. price of €343.40 (22.3% below fair value)
  • GF Score™: 89/100 with 7 warning signs

No single metric tells the full story. See the XTER:A58 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Elevance Health Business Description

Address 220 Virginia Avenue, Indianapolis, IN, USA, 46204
Elevance Health remains one of the leading health insurers in the US, providing medical benefits to 45 million medical members at the end of 2025. The company offers employer, individual, and government-sponsored coverage plans. Elevance differs from its peers in its unique position as the largest single provider of Blue Cross Blue Shield branded coverage, operating as the licensee for the Blue Cross Blue Shield Association in 14 states. Through acquisitions, such as the Amerigroup deal in 2012 and MMM in 2021, Elevance's reach expands beyond those states in government-sponsored programs, such as Medicaid and Medicare Advantage plans, too. It is also an emerging player in pharmacy benefit management and other healthcare services.
89GF Score

Get the complete analysis for XTER:A58

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€343.40
Price
€441.91
GF Value